Somnus Medical floats to raise $42 million:
This article was originally published in Clinica
Somnus Medical Technologies, which manufactures products for the treatment of upper airway disorders, has raised $42 million in an initial public offering in the US. The company sold four million shares at $10.50 each. Somnus' products use its radiofrequency technology. In July the company received FDA approval for its Somnoplasty system for the treatment of habitual snoring (see Clinica No 768, p 13). The product uses radiofrequency energy to ablate part of the soft palate and uvula.